FDA Ephedrine Rule Cost-Benefit Analysis Needs Further Explanation - GAO

FDA should be required to better explain the factors used in its cost-benefit analysis of the expected effects of the ephedrine proposed rule, the General Accounting Office states in a report on the rule released Aug. 4.